The multifunctional glycolytic enzyme α-enolase (ENO1) has been shown to be commonly over-expressed in tumors [9, 12, 23], and is thus a promising and clinically-relevant molecular target for immunotherapeutic approaches, particularly in pancreatic cancer [10, 13, 24]. This evidence concerns the gene HK1 and familial pancreatic carcinoma.